title: Relationship between CYP17 gene polymorphisms and risk of prostate cancer.
abstract: Cytochrome P450 17a-hydroxylase (CYP17) plays a critical role in androgen biosynthesis. Polymorphisms of the CYP17 promoter have been proposed as risk factors for prostate cancer; however, some studies have produced inconclusive or controversial results. We investigated the relationship between polymorphisms of the CYP17 gene and the risk of prostate cancer. A total of 176 patients with prostate cancer were enrolled in the study, and 168 healthy individuals acted as the control group. The participants were divided into those <71 years old and those ≥71 years old. Restriction fragment length polymorphism-polymerase chain reaction was used to confirm the genotype of CYP17 in the samples. The prostate-specific antigen (PSA) concentrations were also measured in all subjects. When T/C and C/C were compared with T/T, the ORs were 0.478 (P = 0.489) and 0.814 (P = 0.367), respectively. There was no significant difference in PSA concentration among the three genotypes in the <71 group, whereas there were statistically significant differences in the ≥71 group (P = 0.003 and 0.012, respectively). There was no significant difference in free PSA and total PSA levels between the three groups and the control group. The T/C and C/C genotypes were not associated with the risk of prostate cancer, and there were no significant differences between them. In the ≥71 group, the T/C and C/C genotypes were closely associated with prostate cancer, which suggests that the CYP17 gene might be a risk factor for prostate cancer in males of advanced age.
authors.affiliation: Centre for Preclinical Medicine, SiChuan Medical College, Luzhou, Sichuan, China.
authors.forename: J
authors.initials: J
authors.lastname: Song
authors.affiliation: Centre for Preclinical Medicine, SiChuan Medical College, Luzhou, Sichuan, China.
authors.forename: Z-H
authors.initials: ZH
authors.lastname: Tao
authors.affiliation: Centre for Preclinical Medicine, SiChuan Medical College, Luzhou, Sichuan, China.
authors.forename: X-Y
authors.initials: XY
authors.lastname: Liu
authors.affiliation: Centre for Preclinical Medicine, SiChuan Medical College, Luzhou, Sichuan, China.
authors.forename: S
authors.initials: S
authors.lastname: Gong
authors.affiliation: Centre for Preclinical Medicine, SiChuan Medical College, Luzhou, Sichuan, China.
authors.forename: L
authors.initials: L
authors.lastname: Gan
mesh_terms: D000367:Age Factors; D000368:Aged; D016022:Case-Control Studies; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D013254:Steroid 17-alpha-Hydroxylase / Q000235:genetics*
chemical_list: C501892:CYP17A1 protein, human; D013254:Steroid 17-alpha-Hydroxylase; D017430:Prostate-Specific Antigen